Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Endotoxin/LPS
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MixedEndotoxin/LPSC57BL/6Malen = Mouse group sizes not stated; human cohort 54 patients with…Intraperitoneal5 mg/kg body weight2 hours before intravenous lipopolysaccharide
Model: Chronic liver injury with carbon tetrachloride 0.5 mL/kg intraperitoneally twice weekly for 2 weeks, followed by lipopolysaccharide 2.5 mg/kg intravenously to produce acute-on-chronic injury
Recombinant PTX3 attenuated lipopolysaccharide-induced liver injury, inflammation and cell recruitment, and PTX3 expression was raised in patients with alcoholic hepatitis in proportion to disease severity.
Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.